Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Fig. 2

a. Kaplan–Meier analysis of progression-free survival and duration of disease control. Median progression-free survival and duration of disease control were 12.4 months (95% CI: 10.0–14.8 months) and 13.4 months (95% CI: 12.2–14.6 months), respectively. PFS, progression-free survival; DDC, duration of disease control; CI, confidence interval; N, number of patients. b. Kaplan–Meier analysis of overall survival. Median overall survival was 30.6 months (95% CI: 27.6–33.5 months). OS, overall survival, OS; CI, confidence interval; N, number of patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us